MeiraGTx reports sustained benefits from gene therapy trial at 3 years

April 16, 2026 7:01 AM

MeiraGTx Holdings plc (NASDAQ: MGTX) announced three-year data from its Phase 1 AQUAx study showing sustained improvements in patients treated ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found